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Objectives: To assess the economic burden and health care resource utili-
zation among patients in long-term care facilities who were diagnosed with 
stroke. MethOds: Patients diagnosed with stroke (International Classification of 
Diseases, 9th Revision, Clinical Modification diagnosis codes 433, 434 and 436) were 
identified using the Long Term Care Minimum Data Set (MDS) linked to 5% Medicare 
data from 01JAN2009 through 31DEC2010. The initial diagnosis date was designated 
as the index date. Patients without a stroke diagnosis (control cohort) were matched 
to stroke patients, and 1:1 propensity score matching (PSM) was used to control for 
age, region, gender and baseline Charlson Comorbidity Index score. The index date 
for the control cohort was randomly chosen to reduce selection bias. Patients in 
both cohorts were required to be age ≥ 65 years, have at least two consecutive quar-
terly assessments documented in MDS data 6 months prior to the index date and 
have continuous medical and pharmacy benefits 1 year before and after the index 
date. Results: Once PSM was applied, 1,014 patients were included in each cohort, 
and baseline characteristics were balanced. A higher percentage of stroke patients 
had inpatient admissions (40.34% vs. 23.37%, p< 0.0001), outpatient visits (92.31% 
vs. 89.45%, p= 0.0253), skilled nursing facility (SNF; 37.67% vs. 28.21%, p< 0.0001) and 
durable medical equipment (DME) claims (30.47% vs. 22.09%, p< 0.0001) than those 
in the control cohort. Stroke patients also incurred considerably higher inpatient 
($7,068 vs. $3,418, p< 0.0001), outpatient ($3,545 vs. $2,539, p< 0.0001), SNF ($8,036 vs. 
$3,695, p< 0.0001), DME ($394 vs. $235, p= 0.0023) and carrier claim costs ($3,606 vs. 
$2,489, p< 0.0001) than those without a stroke diagnosis. cOnclusiOns: Patients 
diagnosed with stroke had considerably higher health care resource utilization and 
costs than those in the control cohort.
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Objectives: To assess the economic burden of the management of hypertension 
and diabetes in two tertiary health facilities in Bayelsa State, Niger Delta, South-
south Nigeria. MethOds: It is a retrospective review of randomly selected case 
notes of 531 hypertensive and diabetic patients. The demographics and cost of 
medicines prescribed were reviewed based on the hospital prices. These patients 
were randomly selected from those who attended the endocrinology and cardiol-
ogy clinics of the health facilities in 2011 and 2012. Results: Mean patients’ age 
was 55.70±12.23 years. Most (42.2%) of them were civil servants while the rest were 
petty business owners (26.6%), retired workers (14.9%), farmers (10.3%), or unem-
ployed (6%). The monthly average costs of all prescribed medications per patient 
for initiation and maintenance of therapy were ₦3333.43±2317.40 (US$18.17±12.60) 
and ₦4458.09±3064.8 (US$24.30±16.70) respectively (p < 0.05). Diuretics and sulpho-
nylureas were the most economical of all the drugs prescribed monthly per patient 
accounting for ₦531.70 [US$2.90] and ₦559.10 [US$3.10] respectively for initiation 
of therapy, and ₦768.1 [US$4.20] and ₦631.1 [US$3.40] for maintenance of therapy. 
However, the most expensive of all the medicines were angiotensin receptor blockers 
which accounted for ₦4,368.8 [US$23.8] for initiation and ₦4,810.50 [US$26.20] for 
maintenance of therapy as well as insulins (at ₦2,448.20 [US$13.30] for initiation 
and ₦2,457.10 [US$13.40] for maintenance of therapy). cOnclusiOns: Considering 
the poverty level in the Niger Delta region of Nigeria, the medication cost burden 
of managing hypertension and diabetes is high and unaffordable by most of the 
patients.
PCV52
Estimating thE Cost of illnEss of giant CEll artEritis
Babigumira J.B.1, Li M.1, Boudreau D.M.1, Best J.H.2, Garrison L.P.1
1University of Washington, Seattle, WA, USA, 2Genentech, Inc, South San Francisco, CA, USA
Objectives: Giant cell arteritis (GCA), a chronic vasculitis commonly presenting 
with headache, affects approximately 230,000 individuals in the US. However, lim-
ited data exist on the health care resource utilization and costs that are attributable 
to GCA. The objective of this study was to estimate the cost of illness in patients with 
GCA in the US. MethOds: A retrospective cohort of patients with a new diagnosis 
of GCA and five matched controls was identified from a large US claims database 
between January 1st 2008 and December 31st2011. Newly diagnosed GCA patients 
were defined by a diagnosis of GCA (ICD-9 446.5) during the study period and no GCA 
diagnosis in the 12 months prior. Controls were defined by absence of a GCA diag-
nosis. GCA patients and controls were matched on age, gender, region, index year of 
diagnosis, and index month of diagnosis. One-year healthcare costs were compared 
among cases and controls, adjusting for age, gender, Charlson Comorbidity Index 
(CCI), chronic disease count, U.S. region, health plan type (HMO vs. other), and year 
using generalized linear models. Results: A cohort of 11,245 GCA patients and 
56,230 controls was identified. The mean age of the cohort was 70 years and 71% 
were females. Mean CCI was 1.6 for GCA patients and 0.8 for controls. Mean one-
year cost for GCA patients was $26,400 (SD: $48,500) and mean one-year cost for 
controls was $11,500 (SD: $29,200). After multivariate adjustment, the difference 
in one-year cost between GCA patients and controls was $4,800 (95% CI: $4,080—
$5,520). cOnclusiOns: Patients with GCA experience increased healthcare costs 
compared to patients without GCA after adjusting for covariates related to health 
care resource utilization and costs. Our results are the first to inform researchers, 
clinicians, and policymakers on the cost burden of GCA, estimated to be approxi-
mately $1 billion annually in the US.
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simulations were performed to propagate the uncertainty of parameters. Results: 
The expected cost (and its credibility intervals of 95%) of the prevalent popula-
tion with AH, DM and dyslipidemia using prices from public health system 
was in Chilean pesos (CLP$) CLP$12,463MM (CLP$11,394MM – CLP$13,622MM), 
CLP$36,425MM (CLP$25,603MM – CLP$49,624MM) and CLP$20,658MM (CLP$11,090MM 
– CLP$33,284MM) respectively. While, the estimated cost based on private health 
system was CLP$700,613MM (CLP$561,764MM – CLP$865,354MM), CLP$333,921MM 
(CLP$253,963MM – CLP$436,879MM) and CLP$680,919MM (CLP$327,916MM – 
CLP$1,645,906MM) respectively. cOnclusiOns: The expected cost needed for the 
treatment of the three conditions studied represent 1.3% and 2.9% in the worst case 
scenario (33% considering private system prices) of the 2014 health budget, and the 
effort to improve the subdiagnostic of these conditions would determine a budget 
impact of at least 0.86%, only with pharmacological treatment.
PCV48
Cost-EffECtiVEnEss analysis and BudgEt imPaCt of ConCor® 
am VErsus BisoProlol Plus amlodiPinE in systEmiC artErial 
hyPErtEnsion trEatmEnt, from thE PErsPECtiVE of thE Brazilian 
PuBliC hEalth systEm
Fujii R.K.1, Restrepo M.2, Fernandes R.A.3, Haas L.3, Pepe C.4, Junqueira M.1
1Merck Serono, São Paulo, Brazil, 2Merck Serono, Bogota, Colombia, 3Grupo Resulta, São Paulo, 
Brazil, 4NewBD/Medinsight - Grupo Resulta, São Paulo, Brazil
Objectives: Systemic arterial hypertension (SAH) is a chronic condition, and 
despite the large number of available antihypertensive drugs, patients with SAH 
who are drug-treated frequently do not obtain goal Blood Pressure (BP) levels. A 
combination of drugs is recommended for those cases, however, compliance is 
improved when agents are prescribed as fixed dose combinations rather than sepa-
rate pills. A combination of bisoprolol and amlodipine once a day showed a rapid 
reduction of BP after 4 weeks. The aim of this paper is to perform cost-effectiveness 
(CE) and budget impact (BI) analyses of Concor® AM compared to amlodipine + 
bisoprolol as separate tablets. MethOds: A daily-cycle markov model was built 
considering the outcomes: days on treatment; number of events (stroke, myocardial 
infarction, heart failure and angina); number of full-lifetime-patients with transitory 
drug interruption (non-compliance); number of full-lifetime-patients with normal 
blood pressure and days of life. Efficacy data were obtained from literature review 
and unit costs were obtained from official price lists. The time horizon of the CE 
and BI model was 30 and 10 years, respectively. A 5% annual discount rate was 
applied in costs and benefits in the CE model. Results: Concor® AM increased 
overall survival in 43 days and assured more 2,090 days on treatment, per patient, 
during lifetime period. Also, reduced 183 events, and allowed more 187 patients 
with controlled blog pressure, per 1,000 patients. Concor® AM was dominant vs. 
Concor + Amlodipine, resulting in financial resource saving of approximately 8.1% 
(BRL 5,720.72 per patient). Additionally, the use of Concor® AM in patients with 
SAH resulted in financial resource saving of approximately BRL 300,321,412.45, in 
the period from 2014 to 2025. cOnclusiOns: Fixed-dose combinations such as 
Concor-AM do represent an opportunity to increase compliance and consequently 
health outcomes and its costs.
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Objectives: The objective of this study was to estimate the overall differences 
in medical costs when nonvalvular atrial fibrillation and venous thromboembo-
lism (VTE) patients are treated with each of the new oral anticoagulants (NOACs), 
dabigatran, rivaroxaban, apixaban, and edoxaban vs. warfarin. MethOds: Medical 
cost differences associated with NOAC use for patients treated for NVAF and acute 
VTE were obtained from previous publications and were based on clinical event 
rates from clinical trials. The medical cost differences associated with edoxaban 
vs. warfarin among NVAF patients were estimated as done previously for other 
NOACs. A hypothetical health plan population with 1 million members was used to 
estimate and compare the medical cost differences associated with use of each of 
the NOACs vs. warfarin among the combined NVAF and VTE populations. Prevalence 
rates of NVAF and VTE were derived from published literature. The same hypotheti-
cal usage rate (i.e. 10%) for each NOAC was assumed to facilitate the comparison of 
the medical cost differences. The medical cost differences of NOACs vs. warfarin 
were projected in the years 2015-2018. Results: In 2014, in a hypothetical popula-
tion of 1 million health plan members, medical costs were estimated to be reduced 
by the greatest amount for NVAF and VTE patients treated with apixaban ($11.5 
million), followed by those treated with edoxaban ($6.6 million), rivaroxaban ($4.2 
million), and dabigatran ($3.7 million). Medical cost savings associated with use of 
any of the NOACs were projected to increase from 2014 to 2018. cOnclusiOns: 
Based on our economic analysis using clinical trial data, treatment of patients with 
NVAF and VTE with any of the NOACs instead of warfarin is associated with sav-
ings in medical costs, with apixaban being associated with the greatest savings in 
medical costs. The direct application of the results to the real-world setting will 
require further assessment.
PCV50
a rEtrosPECtiVE analysis of hEalth CarE rEsourCE utilization and 
thE EConomiC BurdEn among u.s. long-tErm CarE faCility PatiEnts 
diagnosEd with strokE
Huang A.1, Shrestha S.1, Baser O.2, Yuce H.3, Wang L.1
1STATinMED Research, Plano, TX, USA, 2STATinMED Research, The University of Michigan, MEF 
University, Ann Arbor, MI, USA, 3City University of New York & STATinMED Research, New York, 
NY, USA
